Jul 6, 2020
As the director of The University of Arizona Cancer Center's Clinical Trials Office, and national expert in pancreatic and biliary cancers, Rachna Shroff, MD, shares the impact COVID-19 has had on our patients, clinical trials, and cancer care.
About Dr. Shroff :21
The interview 1:45
How did you end up in GI medical oncology? 1:52
You’ve become a nationally known leader in the biliary space 4:45
How has your clinical practice changed, and how has clinical trial enrollment changed since COVID-19? 6:08
Many clinical trial modifications occurred so quickly; how do you think that was possible? 14:10
What has changed the most for you since COVID-19 began? 10:38
Things have been moving quickly to be more nimble than usual 16:23
Are you concerned about the impact this will have on our patients after the acuity of COVID-19? 17:50
Do you think we’ll see flexibility in treatment plans going forward? 20:42
Do you think clinical trials will be able to incorporate telehealth for check-ins? 22:30
What are your thoughts on how trials/studies/data have been presented about COVID-19 in general? 28:05
How do you help people navigate the data? 31:14
What are you optimistic about for the future? 35:54
How to get in touch with Dr. Shroff 39:23
Rachna T. Shroff, MD, MS, is an associate professor in the division of hematology and oncology; chief of the Section of GI Medical Oncology; leader of the GI Disease-Oriented Team; and director of the Clinical Trials Office at The University of Arizona Cancer Center.
Disclosures: Jain reports she is a paid freelance writer for Lippincott. Shroff reports she has received research funding from Exelixis, Halozyme, Merck, Pieris and Taiho, and has served as an advisory board member for Agios, Clovis Oncology, Debiopharm, Exelixis, Merck, QED Therapeutics and Seattle Genetics.